Clinical trialPhase 1 / Phase 2Terminated
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
- Outcome
- Stopped early. Results posted; single-arm, no comparisonSponsor decision (Business decision)
- Phase
- Phase 1 / Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 30 April 2018
- Ended
- 12 October 2021
- Enrollment
- 48 participants
- Sites
- 6
- Primary outcomes
- Number of Participants With Dose Limiting Toxicities (DLTs); Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs); Number of Participants With >= Grade 3 Laboratory Results
- Sponsor type
- Industry
- Results posted
- 12 December 2022
- Last update
- 1 August 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 1 August 2023
- DLT/MTD
- Number of Participants With Dose Limiting Toxicities (DLTs)Biweekly Regimen (GEN1029 0.1 mg/kg): 0 of 10Biweekly Regimen (GEN1029 0.2 mg/kg): 1 of 6Biweekly Regimen (GEN1029 0.3 mg/kg): 0 of 3Biweekly Regimen (GEN1029 1.0 mg/kg): 3 of 10Biweekly Regimen (GEN1029 2.0 mg/kg): 3 of 7Biweekly Regimen (GEN1029 3.0 mg/kg): 2 of 5Values: ParticipantsTime frame: From Day 1 to 28 days after the first dose of study drugNo analysis posted for this outcome (outcome 1)
- Primary outcome
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Any TEAE: Biweekly Regimen (GEN1029 0.1 mg/kg): 8 of 10Any TEAE: Biweekly Regimen (GEN1029 0.2 mg/kg): 7 of 7Any TEAE: Biweekly Regimen (GEN1029 0.3 mg/kg): 4 of 4Any TEAE: Biweekly Regimen (GEN1029 1.0 mg/kg): 11 of 11Any TEAE: Biweekly Regimen (GEN1029 2.0 mg/kg): 7 of 7Any TEAE: Biweekly Regimen (GEN1029 3.0 mg/kg): 7 of 7Any TESAE: Biweekly Regimen (GEN1029 0.1 mg/kg): 3 of 10Any TESAE: Biweekly Regimen (GEN1029 0.2 mg/kg): 3 of 7Any TESAE: Biweekly Regimen (GEN1029 0.3 mg/kg): 2 of 4Any TESAE: Biweekly Regimen (GEN1029 1.0 mg/kg): 9 of 11Any TESAE: Biweekly Regimen (GEN1029 2.0 mg/kg): 6 of 7Any TESAE: Biweekly Regimen (GEN1029 3.0 mg/kg): 4 of 7Values: ParticipantsTime frame: Day 1 through Day 565 (corresponding to maximum observed duration)No analysis posted for this outcome (outcome 2)
- Primary outcome
- Number of Participants With >= Grade 3 Laboratory ResultsActivated partial thromboplastin time prolonged: Biweekly Regimen (GEN1029 0.1 mg/kg): 0 of 10Activated partial thromboplastin time prolonged: Biweekly Regimen (GEN1029 0.2 mg/kg): 1 of 7Activated partial thromboplastin time prolonged: Biweekly Regimen (GEN1029 0.3 mg/kg): 0 of 4Activated partial thromboplastin time prolonged: Biweekly Regimen (GEN1029 1.0 mg/kg): 0 of 11Activated partial thromboplastin time prolonged: Biweekly Regimen (GEN1029 2.0 mg/kg): 0 of 7Activated partial thromboplastin time prolonged: Biweekly Regimen (GEN1029 3.0 mg/kg): 0 of 7Alanine aminotransferase increased: Biweekly Regimen (GEN1029 0.1 mg/kg): 1 of 10Alanine aminotransferase increased: Biweekly Regimen (GEN1029 0.2 mg/kg): 1 of 7Alanine aminotransferase increased: Biweekly Regimen (GEN1029 0.3 mg/kg): 2 of 4Alanine aminotransferase increased: Biweekly Regimen (GEN1029 1.0 mg/kg): 3 of 11Alanine aminotransferase increased: Biweekly Regimen (GEN1029 2.0 mg/kg): 1 of 7Alanine aminotransferase increased: Biweekly Regimen (GEN1029 3.0 mg/kg): 2 of 7Alkaline phosphatase increased: Biweekly Regimen (GEN1029 0.1 mg/kg): 0 of 10Alkaline phosphatase increased: Biweekly Regimen (GEN1029 0.2 mg/kg): 0 of 7Alkaline phosphatase increased: Biweekly Regimen (GEN1029 0.3 mg/kg): 1 of 4Alkaline phosphatase increased: Biweekly Regimen (GEN1029 1.0 mg/kg): 0 of 11Alkaline phosphatase increased: Biweekly Regimen (GEN1029 2.0 mg/kg): 1 of 7Alkaline phosphatase increased: Biweekly Regimen (GEN1029 3.0 mg/kg): 0 of 7Amylase increased: Biweekly Regimen (GEN1029 0.1 mg/kg): 0 of 10Amylase increased: Biweekly Regimen (GEN1029 0.2 mg/kg): 1 of 7Amylase increased: Biweekly Regimen (GEN1029 0.3 mg/kg): 1 of 4Amylase increased: Biweekly Regimen (GEN1029 1.0 mg/kg): 0 of 11Amylase increased: Biweekly Regimen (GEN1029 2.0 mg/kg): 0 of 7Amylase increased: Biweekly Regimen (GEN1029 3.0 mg/kg): 0 of 7Asparate aminotransferase increased: Biweekly Regimen (GEN1029 0.1 mg/kg): 1 of 10Asparate aminotransferase increased: Biweekly Regimen (GEN1029 0.2 mg/kg): 2 of 7Asparate aminotransferase increased: Biweekly Regimen (GEN1029 0.3 mg/kg): 0 of 4Asparate aminotransferase increased: Biweekly Regimen (GEN1029 1.0 mg/kg): 0 of 11Asparate aminotransferase increased: Biweekly Regimen (GEN1029 2.0 mg/kg): 0 of 7Asparate aminotransferase increased: Biweekly Regimen (GEN1029 3.0 mg/kg): 2 of 7Bilirubin increased: Biweekly Regimen (GEN1029 0.1 mg/kg): 0 of 10Bilirubin increased: Biweekly Regimen (GEN1029 0.2 mg/kg): 0 of 7Bilirubin increased: Biweekly Regimen (GEN1029 0.3 mg/kg): 0 of 4Bilirubin increased: Biweekly Regimen (GEN1029 1.0 mg/kg): 1 of 11Bilirubin increased: Biweekly Regimen (GEN1029 2.0 mg/kg): 0 of 7Bilirubin increased: Biweekly Regimen (GEN1029 3.0 mg/kg): 0 of 7Values: ParticipantsTime frame: Day 1 through Day 565 (corresponding to maximum observed duration)6 of 17 rows shownNo analysis posted for this outcome (outcome 3)
- Participants
- Biweekly Regimen (GEN1029 0.1 mg/kg): 10 started, 1 completedBiweekly Regimen (GEN1029 0.2 mg/kg): 7 started, 2 completedBiweekly Regimen (GEN1029 0.3 mg/kg): 4 started, 0 completedBiweekly Regimen (GEN1029 1.0 mg/kg): 11 started, 0 completedBiweekly Regimen (GEN1029 2.0 mg/kg): 7 started, 0 completedBiweekly Regimen (GEN1029 3.0 mg/kg): 7 started, 0 completedPriming Regimen (GEN1029 0.1 mg/kg): 1 started, 0 completedIntensified Regimen (GEN1029 1.0 mg/kg): 1 started, 0 completed
- Serious adverse events
- Biweekly Regimen (GEN1029 0.1 mg/kg): 3 of 10Biweekly Regimen (GEN1029 0.2 mg/kg): 3 of 7Biweekly Regimen (GEN1029 0.3 mg/kg): 2 of 4Biweekly Regimen (GEN1029 1.0 mg/kg): 9 of 11Biweekly Regimen (GEN1029 2.0 mg/kg): 6 of 7Biweekly Regimen (GEN1029 3.0 mg/kg): 4 of 7Priming Regimen (GEN1029 0.1 mg/kg): 0 of 1Intensified Regimen (GEN1029 1.0 mg/kg): 1 of 1Participants with at least one serious adverse event, of those at risk, as posted
15 secondary outcomes, the first 8 shown
- Maximum Observed Plasma Concentration (Cmax) of Hx-DR5-01 and Hx-DR5-05
- Cmax Hx-DR5-01 Cycle 1 (Day 1): Biweekly Regimen (GEN1029 0.1 mg/kg) 0.86 (36.8), n=9; Biweekly Regimen (GEN1029 0.2 mg/kg) 1.90 (38.0), n=6; Biweekly Regimen (GEN1029 0.3 mg/kg) 2.81 (28.9), n=4; Biweekly Regimen (GEN1029 1.0 mg/kg) 9.79 (20.9), n=11; Biweekly Regimen (GEN1029 2.0 mg/kg) 21.31 (24.6), n=7; Biweekly Regimen (GEN1029 3.0 mg/kg) 29.75 (24.9), n=6 [geometric mean µg/mL, Geometric Coefficient of Variation] (first of 6 rows)
- Area Under Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-inf]) of Hx-…
- AUC(0-inf) Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) 39.44 (50.2), n=8; Biweekly Regimen (GEN1029 0.2 mg/kg) 91.20 (66.0), n=6; Biweekly Regimen (GEN1029 0.3 mg/kg) 85.80 (56.7), n=4; Biweekly Regimen (GEN1029 1.0 mg/kg) 523.66 (47.5), n=11; Biweekly Regimen (GEN1029 2.0 mg/kg) 1298.0 (22.7), n=7; Biweekly Regimen (GEN1029 3.0 mg/kg) 1497.7 (58.7), n=6 [geometric mean µg*h/mL, Geometric Coefficient of Variation] (first of 6 rows)
- Area Under Plasma Concentration-time Curve From Time Zero to the Time of Last Nonzero Con…
- AUC(0-Clast) Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) 24.36 (73.2), n=9; Biweekly Regimen (GEN1029 0.2 mg/kg) 72.25 (70.6), n=6; Biweekly Regimen (GEN1029 0.3 mg/kg) 60.78 (35.8), n=4; Biweekly Regimen (GEN1029 1.0 mg/kg) 460.37 (43.5), n=11; Biweekly Regimen (GEN1029 2.0 mg/kg) 1173.7 (15.6), n=7; Biweekly Regimen (GEN1029 3.0 mg/kg) 1058.9 (88.6), n=6 [geometric mean µg*h/mL, Geometric Coefficient of Variation] (first of 6 rows)
- Total Clearance (CL) of Hx-DR5-01 and Hx-DR5-05
- CL Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) 95.98 (53.8), n=8; Biweekly Regimen (GEN1029 0.2 mg/kg) 91.27 (51.4), n=6; Biweekly Regimen (GEN1029 0.3 mg/kg) 123.75 (69.9), n=4; Biweekly Regimen (GEN1029 1.0 mg/kg) 65.36 (56.5), n=11; Biweekly Regimen (GEN1029 2.0 mg/kg) 59.07 (31.4), n=7; Biweekly Regimen (GEN1029 3.0 mg/kg) 69.50 (51.0), n=6 [geometric mean mL/h, Geometric Coefficient of Variation] (first of 6 rows)
- Volume of Distribution (Vss) at Steady State of Hx-DR5-01 and Hx-DR5-05
- Vss Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) 5366.8 (35.0), n=8; Biweekly Regimen (GEN1029 0.2 mg/kg) 4788.6 (5.0), n=6; Biweekly Regimen (GEN1029 0.3 mg/kg) 3666.8 (49.4), n=4; Biweekly Regimen (GEN1029 1.0 mg/kg) 3834.6 (34.3), n=11; Biweekly Regimen (GEN1029 2.0 mg/kg) 4885.9 (18.8), n=7; Biweekly Regimen (GEN1029 3.0 mg/kg) 4127.3 (19.2), n=6 [geometric mean mL, Geometric Coefficient of Variation] (first of 6 rows)
- Half-life Lambda-z (t1/2) of Hx-DR5-01 and Hx-DR5-05
- T1/2 Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) 41.69 (20.7 to 61.1), n=8; Biweekly Regimen (GEN1029 0.2 mg/kg) 41.31 (16.6 to 60.3), n=6; Biweekly Regimen (GEN1029 0.3 mg/kg) 18.10 (11.4 to 40.5), n=4; Biweekly Regimen (GEN1029 1.0 mg/kg) 40.27 (5.1 to 66.8), n=11; Biweekly Regimen (GEN1029 2.0 mg/kg) 70.90 (50.5 to 86.2), n=7; Biweekly Regimen (GEN1029 3.0 mg/kg) 42.45 (17.9 to 80.5), n=6 [median h, Full Range] (first of 6 rows)
- Time to Reach Maximum Observed Concentration (Tmax) of Hx-DR5-01 and Hx-DR5-05
- Tmax Hx-DR5-01 Cycle 1 Day 1: 1. Biweekly Regimen (GEN1029 0.1 mg/kg) 1.58 (1.1 to 5.8), n=9; 2. Biweekly Regimen (GEN1029 0.2 mg/kg) 1.89 (1.4 to 5.0), n=6; 3. Biweekly Regimen (GEN1029 0.3 mg/kg) 1.23 (1.2 to 1.4), n=4; 4. Biweekly Regimen (GEN1029 1.0 mg/kg) 2.00 (0.1 to 4.7), n=11; 5. Biweekly Regimen (GEN1029 2.0 mg/kg) 1.30 (1.1 to 3.6), n=7; 6. Biweekly Regimen (GEN1029 3.0 mg/kg) 1.46 (1.0 to 3.1), n=6 [median h, Full Range] (first of 6 rows)
- Plasma Concentration of Hx-DR5-01 and Hx-DR5-05
- Plasma concentration Hx-DR5-01 Cycle 1 Day 1 (pre…: Biweekly Regimen (GEN1029 0.1 mg/kg) 0.085 (38.5), n=9; Biweekly Regimen (GEN1029 0.2 mg/kg) 0.075 (0.0), n=7; Biweekly Regimen (GEN1029 0.3 mg/kg) 0.075 (0.0), n=4; Biweekly Regimen (GEN1029 1.0 mg/kg) 0.075 (0.0), n=11; Biweekly Regimen (GEN1029 2.0 mg/kg) 0.075 (0.0), n=7; Biweekly Regimen (GEN1029 3.0 mg/kg) 0.075 (0.0), n=6 [geometric mean µg/mL, Geometric Coefficient of Variation] (first of 6 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
Detailed description public domain (ClinicalTrials.gov)
The trial is an open-label, multi-center first-in-human trial of GEN1029 (HexaBody®-DR5/DR5). The trial consists of two parts a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.
Intervention public domain (ClinicalTrials.gov)
Biological: GEN1029 (HexaBody®-DR5/DR5). GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
Arm public domain (ClinicalTrials.gov)
GEN1029 (HexaBody®-DR5/DR5) (experimental):
Primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Dose Limiting Toxicities (DLTs). DLT criteria in the dose escalation phase of this trial are defined as hematologic toxicity including Grade (G) 4 neutropenia/thrombocytopenia for minimal duration of 7 days, G3/4 febrile neutropenia, \>=G3 thrombocytopenia with bleeding, or G4 anemia; and non-hematologic toxicity including G4 infusion-related reactions (IRR) or anaphylaxis, G3 IRR did not resolve to =\<G1 within 24 hours, \>=G3 diarrhea/vomiting (did not respond to optimal treatment within 2 days), G3 nausea (did not respond to optimal treatment within 7days), or Hy's law or protocol-specified toxicities related to liver function test results or amylase and/or lipase elevations; or any \>=G3 possibly related non-hematological AE, which occurred during first 2 cycles (as specified in protocol). Time frame: From Day 1 to 28 days after the first dose of study drug.
Primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs). An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above \[medical and scientific judgment must be exercised in deciding whether an AE is 'medically important'\]); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening during the treatment period including the safety follow-up period. Time frame: Day 1 through Day 565 (corresponding to maximum observed duration).
Primary outcome public domain (ClinicalTrials.gov)
Number of Participants With >= Grade 3 Laboratory Results. Number of participants with laboratory measurements of Grade \>= 3 by NCI-CTCAE v4.03 are reported. The NCI-CTCAE is a descriptive terminology is used for AE reporting. The NCI-CTCAE v4.03 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE. Based on this general guideline: Grade 1 as mild AE, Grade 2 as moderate AE, Grade 3 as severe AE, Grade 4 as life-threatening or disabling AE, and Grade 5 as death. In case a participant reported multiple severity grades for an AE, only the maximum grade was used. Time frame: Day 1 through Day 565 (corresponding to maximum observed duration).
Secondary outcome public domain (ClinicalTrials.gov)
Maximum Observed Plasma Concentration (Cmax) of Hx-DR5-01 and Hx-DR5-05. Time frame: Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3.
Secondary outcome public domain (ClinicalTrials.gov)
Area Under Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-inf]) of Hx-DR5-01 and Hx-DR5-05. Time frame: Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3.
Secondary outcome public domain (ClinicalTrials.gov)
Area Under Plasma Concentration-time Curve From Time Zero to the Time of Last Nonzero Concentration (AUC[0-Clast]) of Hx-DR5-01 and Hx-DR5-05. Time frame: Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3.
Secondary outcome public domain (ClinicalTrials.gov)
Total Clearance (CL) of Hx-DR5-01 and Hx-DR5-05. Time frame: Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3.
Secondary outcome public domain (ClinicalTrials.gov)
Volume of Distribution (Vss) at Steady State of Hx-DR5-01 and Hx-DR5-05. Time frame: Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3.
Secondary outcome public domain (ClinicalTrials.gov)
Half-life Lambda-z (t1/2) of Hx-DR5-01 and Hx-DR5-05. Time frame: Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria (main): * Patients with advanced and/or metastatic cancer who have no available standard therapy or who are not candidates for available standard therapy, and for whom, in the opinion of the investigator, experimental therapy with GEN1029 may be beneficial. * Patient must be ≥ 18 years of age * Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 * Have an acceptable hematological status * Have an acceptable renal function * Have an acceptable liver function * Have an Eastern Cooperative Oncology Group performance status of 0 or 1 * Body weight ≥ 40kg * Patients both females and males, of childbearing or reproductive potential must agree to use adequate contraception from screening visit until six months after last infusion of GEN1029 Exclusion Criteria (main): * Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 8 weeks prior to first GEN1029 administration * Have clinically significant cardiac disease * Have uncontrolled hypertension as defined in the protocol * Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new (younger than 6 months) or progressive brain metastases or stroke * History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of Investigational Medicinal Product (IMP) * Have received a cumulative dose of corticosteroid ≥ 150 mg prednisone (or equivalent doses of corticosteroids) within two weeks before the first GEN1029 administration * History of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial * Radiotherapy within 14 days prior to first GEN1029 administration * Any prior therapy with a compound targeting DR4 or DR5 * History of chronic liver disease or evidence of hepatic cirrhosis
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 48 participants (actual).
Why stopped public domain (ClinicalTrials.gov)
Sponsor decision
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Dose Limiting Toxicities (DLTs) [From Day 1 to 28 days after the first dose of study drug]. Count Of Participants, Participants. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 0; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=6): 1; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=3): 0; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=10): 3; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 3; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=5): 2.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) [Day 1 through Day 565 (corresponding to maximum observed duration)]. Count Of Participants, Participants. Any TEAE: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 8; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 7; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 4; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 11; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 7; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 7. Any TESAE: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 3; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 3; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 2; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 9; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 6; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 4.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With >= Grade 3 Laboratory Results [Day 1 through Day 565 (corresponding to maximum observed duration)]. Count Of Participants, Participants. Activated partial thromboplastin time prolonged: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 0; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0. Alanine aminotransferase increased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 1; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 2; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 3; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 2. Alkaline phosphatase increased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 0; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0. Amylase increased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 0; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0. Asparate aminotransferase increased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 1; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 2; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 2. Bilirubin increased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 0; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 1; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0. Calcium decreased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 0; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0. Creatinine increased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 1; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0. Gamma-glutamyl transferase increased: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 2; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 2; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 2; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 3; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 1. Glucos
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Maximum Observed Plasma Concentration (Cmax) of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Geometric Mean, µg/mL (Geometric Coefficient of Variation). Cmax Hx-DR5-01 Cycle 1 (Day 1): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.86 (36.8); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.90 (38.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 2.81 (28.9); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 9.79 (20.9); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 21.31 (24.6); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 29.75 (24.9). Cmax Hx-DR5-01 Cycle 2 (Day 1): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.79 (42.9); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 2.11 (18.3); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.12 (59.9); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 8.36 (22.7); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 13.13 (156.3); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 29.56 (7.7). Cmax Hx-DR5-01 Cycle 3 (Day 1): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.89 (16.6); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.82 (53.9); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0.89 (146.4); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 7.20 (11.2); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 20.35 (24.7); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 28.80 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.]. Cmax Hx-DR5-05 Cycle 1 (Day 1): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.87 (45.2); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.81 (35.7); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 2.82 (31.8); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 9.72 (17.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 20.90 (21.9); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 29.44 (27.9). Cmax Hx-DR5-05 Cycle 2 (Day 1): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.79 (25.9); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 2.00 (18.3); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.11 (76.2); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 7.75 (25.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 20.37 (14.3); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 30.52 (5.8). Cmax Hx-DR5-05 Cycle 3 (Day 1): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.87 (26.6); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.28 (93.8); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.62 (108.2); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 6.77 (20.6); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 5.27 (577.8); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 28.50 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Area Under Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-inf]) of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Geometric Mean, µg*h/mL (Geometric Coefficient of Variation). AUC(0-inf) Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 39.44 (50.2); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 91.20 (66.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 85.80 (56.7); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 523.66 (47.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1298.0 (22.7); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 1497.7 (58.7). AUC(0-inf) Hx-DR5-01 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 46.37 (61.5); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 105.32 (55.8); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 35.24 (30.5); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 530.48 (24.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1071.5 (30.7); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2488.5 (10.7). AUC(0-inf) Hx-DR5-01 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 37.43 (74.0); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 53.24 (133.3); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 41.41 (84.9); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 422.32 (26.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1097.8 (36.6); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2653.5 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.]. AUC(0-inf) Hx-DR5-05 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 32.97 (55.4); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 71.21 (66.9); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 83.37 (51.7); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 508.76 (33.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1052.1 (24.7); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 1270.0 (60.1). AUC(0-inf) Hx-DR5-05 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 39.31 (65.9); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 93.11 (66.6); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 44.76 (184.4); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 414.90 (24.1); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 609.90 (55.2); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2273.6 (9.0). AUC(0-inf) Hx-DR5-05 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 25.87 (57.3); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 51.36 (161.6); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 67.23 (200.5); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 231.49 (53.2); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 412.87 (64.1); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2398.5 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Area Under Plasma Concentration-time Curve From Time Zero to the Time of Last Nonzero Concentration (AUC[0-Clast]) of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Geometric Mean, µg*h/mL (Geometric Coefficient of Variation). AUC(0-Clast) Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 24.36 (73.2); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 72.25 (70.6); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 60.78 (35.8); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 460.37 (43.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1173.7 (15.6); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 1058.9 (88.6). AUC(0-Clast) Hx-DR5-01 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 17.34 (141.3); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 70.33 (66.4); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 21.85 (36.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 308.74 (66.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 582.57 (84.8); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2291.4 (18.1). AUC(0-Clast) Hx-DR5-01 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 22.34 (85.9); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 35.31 (151.4); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 6.85 (995.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 385.54 (23.7); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 986.38 (30.1); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2444.7 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.]. AUC(0-Clast) Hx-DR5-05 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 25.41 (120.7); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 53.76 (77.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 53.80 (50.8); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 432.18 (24.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 956.02 (18.8); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 964.48 (91.1). AUC(0-Clast) Hx-DR5-05 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 24.85 (119.4); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 60.75 (76.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 29.17 (165.1); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 258.67 (60.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 395.50 (62.3); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2176.0 (11.7). AUC(0-Clast) Hx-DR5-05 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 20.12 (168.7); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 16.95 (539.4); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 43.56 (405.4); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 158.98 (76.4); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 52.16 (22162.5); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2248.1 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Total Clearance (CL) of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Geometric Mean, mL/h (Geometric Coefficient of Variation). CL Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 95.98 (53.8); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 91.27 (51.4); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 123.75 (69.9); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 65.36 (56.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 59.07 (31.4); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 69.50 (51.0). CL Hx-DR5-01 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 77.36 (70.2); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 79.97 (51.8); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 155.76 (72.6); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 58.07 (31.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 73.43 (28.0); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 36.92 (2.0). CL Hx-DR5-01 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 99.53 (57.1); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 131.46 (76.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 111.33 (12.9); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 62.90 (42.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 62.64 (26.1); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 37.87 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.]. CL Hx-DR5-05 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 111.10 (62.5); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 116.89 (51.3); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 127.35 (69.3); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 67.28 (37.4); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 69.39 (29.2); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 81.96 (53.9). CL Hx-DR5-05 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 90.18 (69.4); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 90.45 (67.1); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 131.51 (240.7); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 79.72 (28.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 134.11 (51.9); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 40.41 (3.7). CL Hx-DR5-05 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 143.09 (50.5); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 140.38 (77.3); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 68.57 (42.2); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 114.74 (59.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 172.66 (78.9); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 41.90 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Volume of Distribution (Vss) at Steady State of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Geometric Mean, mL (Geometric Coefficient of Variation). Vss Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 5366.8 (35.0); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 4788.6 (5.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 3666.8 (49.4); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 3834.6 (34.3); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 4885.9 (18.8); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 4127.3 (19.2). Vss Hx-DR5-01 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 4720.0 (34.9); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 4287.5 (10.5); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 5283.0 (62.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 3998.1 (24.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 4185.8 (17.3); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 3427.5 (25.1). Vss Hx-DR5-01 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 4622.7 (31.1); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 4531.9 (6.7); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 3243.6 (14.3); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 4075.3 (26.2); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 4227.1 (8.7); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 4118.5 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.]. Vss Hx-DR5-05 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 4722.7 (55.6); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 5242.9 (15.8); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 3942.4 (63.6); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 3611.0 (26.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 4291.6 (9.8); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 4142.9 (21.0). Vss Hx-DR5-05 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 4899.3 (22.7); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 4701.6 (15.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 5177.9 (100.6); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 4054.4 (16.4); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 4334.9 (14.9); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 3187.8 (41.0). Vss Hx-DR5-05 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 4812.5 (31.9); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 5077.6 (24.1); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 3577.1 (15.7); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 4951.2 (42.4); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 5130.8 (5.6); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 4173.9 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Half-life Lambda-z (t1/2) of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Median, h (Full Range). T1/2 Hx-DR5-01 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 41.69 (20.7 to 61.1); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 41.31 (16.6 to 60.3); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 18.10 (11.4 to 40.5); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 40.27 (5.1 to 66.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 70.90 (50.5 to 86.2); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 42.45 (17.9 to 80.5). T1/2 Hx-DR5-01 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 37.75 (29.1 to 72.3); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 39.57 (21.7 to 62.5); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 24.47 (16.9 to 29.7); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 49.64 (36.2 to 71.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 33.62 (29.0 to 88.2); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 65.85 (54.6 to 77.1). T1/2 Hx-DR5-01 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 27.64 (16.2 to 84.1); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 19.93 (13.1 to 66.9); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 20.16 (16.2 to 24.1); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 47.86 (30.8 to 60.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 44.51 (40.1 to 64.0); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 77.00 (77.00 to 77.00). T1/2 Hx-DR5-05 Cycle 1 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 35.55 (12.5 to 46.5); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 34.50 (15.6 to 52.5); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 19.10 (14.6 to 44.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 36.33 (26.4 to 70.6); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 42.68 (35.3 to 68.8); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 37.71 (16.6 to 69.6). T1/2 Hx-DR5-05 Cycle 2 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 32.46 (19.3 to 71.4); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 37.71 (17.3 to 80.7); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 25.43 (13.9 to 62.3); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 37.69 (28.4 to 43.5); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 26.68 (13.1 to 29.4); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 51.97 (30.8 to 73.1). T1/2 Hx-DR5-05 Cycle 3 Day 1: Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 25.30 (12.0 to 39.6); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 18.75 (15.4 to 57.4); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 41.26 (24.3 to 58.2); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 33.90 (14.2 to 62.1); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 22.83 (13.2 to 32.5); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 70.9 (70.9 to 70.9).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Time to Reach Maximum Observed Concentration (Tmax) of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Median, h (Full Range). Tmax Hx-DR5-01 Cycle 1 Day 1: 1. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 1.58 (1.1 to 5.8); 2. Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.89 (1.4 to 5.0); 3. Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.23 (1.2 to 1.4); 4. Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 2.00 (0.1 to 4.7); 5. Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1.30 (1.1 to 3.6); 6. Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 1.46 (1.0 to 3.1). Tmax Hx-DR5-01 Cycle 2 Day 1: 1. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 1.25 (1.0 to 3.2); 2. Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 3.03 (3.0 to 5.2); 3. Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.30 (1.1 to 3.2); 4. Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 3.06 (1.1 to 5.1); 5. Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 3.25 (1.1 to 163.7); 6. Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 1.11 (1.0 to 1.2). Tmax Hx-DR5-01 Cycle 3 Day 1: 1. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 1.08 (0.0 to 3.4); 2. Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.48 (1.0 to 2.1); 3. Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.13 (1.1 to 1.3); 4. Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 3.08 (1.4 to 3.5); 5. Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1.82 (1.1 to 3.2); 6. Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 3.1 (3.1 to 3.1). Tmax Hx-DR5-05 Cycle 1 Day 1: 1. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 1.75 (1.1 to 5.4); 2. Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 2.53 (1.0 to 4.8); 3. Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 2.36 (1.2 to 5.5); 4. Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 1.60 (0.1 to 4.7); 5. Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1.35 (1.1 to 3.0); 6. Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 1.46 (1.0 to 3.1). Tmax Hx-DR5-05 Cycle 2 Day 1: 1. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 3.12 (1.1 to 5.1); 2. Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 2.19 (1.0 to 3.5); 3. Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.19 (1.0 to 1.4); 4. Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 2.26 (1.2 to 5.1); 5. Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 2.31 (1.1 to 3.3); 6. Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 2.21 (1.2 to 3.2). Tmax Hx-DR5-05 Cycle 3 Day 1: 1. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 1.08 (0.0 to 1.5); 2. Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.83 (1.0 to 3.3); 3. Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 1.18 (1.1 to 1.3); 4. Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 1.42 (1.1 to 3.0); 5. Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1.13 (1.0 to 1.8); 6. Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 3.1 (3.1 to 3.1).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Plasma Concentration of Hx-DR5-01 and Hx-DR5-05 [Predose, end of infusion, 2, 4, 24, 48, 168 and 336 hours after end of infusion on Day 1 of Cycles 1, 2, 3]. Geometric Mean, µg/mL (Geometric Coefficient of Variation). Plasma concentration Hx-DR5-01 Cycle 1 Day 1 (predose): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.085 (38.5); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0.075 (0.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0.075 (0.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0.075 (0.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0.075 (0.0); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 0.075 (0.0). Plasma concentration Hx-DR5-01 Cycle 2 Day 1 (predose): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.091 (61.0); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0.075 (0.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0.075 (0.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0.084 (34.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0.230 (77.8); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 0.283 (576.2). Plasma concentration Hx-DR5-01 Cycle 3 Day 1 (predose): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.075 (0.0); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0.125 (164.3); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0.075 (0.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0.090 (46.4); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0.224 (156.9); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 0.739 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.]. Plasma concentration Hx-DR5-05 Cycle 1 Day 1 (predose): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.094 (77.6); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0.075 (0.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0.075 (0.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0.075 (0.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0.075 (0.0); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 0.075 (0.0). Plasma concentration Hx-DR5-05 Cycle 2 Day 1 (predose): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.097 (83.6); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0.075 (0.0); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0.075 (0.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0.075 (0.0); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0.155 (161.5); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 0.240 (372.5). Plasma concentration Hx-DR5-05 Cycle 3 Day 1 (predose): Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 0.101 (94.6); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0.119 (138.5); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0.075 (0.0); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0.094 (58.8); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0.075 (0.0); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=6): 0.568 (NA) [Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Antidrug Antibodies (ADAs) Positive to GEN1029 [From Screening (Day -21 to -1) through Day 478 (corresponding to maximum observed duration)]. Count Of Participants, Participants. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 5; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 5; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 4; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 7; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 5; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Change From Baseline in Anti-tumor Activity Measured by Tumor Shrinkage [From Baseline (Day 1) through 8.8 months (corresponding to maximum observed duration)]. Mean, millimeter (Standard Deviation). Biweekly Regimen (GEN1029 0.1 mg/kg) (n=9): 12.0 (11.843); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 12.0 (17.616); Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 13.75 (9.032); Biweekly Regimen (GEN1029 1.0 mg/kg) (n=10): 1.10 (9.049); Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 9.0 (10.909); Biweekly Regimen (GEN1029 3.0 mg/kg) (n=4): 15.50 (18.574).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [From Day 1 through 8.8 months (corresponding to maximum observed duration)]. Count Of Participants, Participants. Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 0; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 0; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 0; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 0; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival (PFS) According to RECIST 1.1 [From Day 1 through 8.8 months (corresponding to maximum observed duration)]. Median, months (95% Confidence Interval). Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 2.5 (0.5 to 3.9); Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 1.4 (0.5 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 2.4 (0.8 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 1.9 (1.2 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 1.2 (1.1 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 1.2 (1.0 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival (OS) According to RECIST 1.1 [From Day 1 through 8.8 months (corresponding to maximum observed duration)]. Median, months (95% Confidence Interval). Biweekly Regimen (GEN1029 0.1 mg/kg) (n=10): 7.0 (2.3 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 0.2 mg/kg) (n=7): 6.4 (1.8 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 0.3 mg/kg) (n=4): 4.9 (NA to NA) [95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 1.0 mg/kg) (n=11): 7.1 (1.7 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 2.0 mg/kg) (n=7): 4.7 (2.8 to NA) [Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.]; Biweekly Regimen (GEN1029 3.0 mg/kg) (n=7): 6.9 (NA to NA) [95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response (DoR) According to RECIST 1.1 [From Day 1 through 8.8 months (corresponding to maximum observed duration)].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Time to Response (TTR) According to RECIST 1.1 [From Day 1 through 8.8 months (corresponding to maximum observed duration)].